Corneal Epithelial Autograft for Pterygium
- Conditions
- Pterygium
- Registration Number
- NCT03217500
- Lead Sponsor
- Chunxiao Wang
- Brief Summary
The purpose of the study is to explore whether femtosecond laser-assisted cornea epithelial autograft is more effective than limbal conjunctival autograft for ocular surface reconstruction after excision of pterygium.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 45
- Age between 18 to 80 years old;
- Primary pterygium, scheduled for elective surgical excision;
- Pterygium encroaching from the nasal side onto the cornea, with less than 180° limbal involvement and without approaching the central visual axis (pupil area);
- Morphologically intact palisades of Vogt in a given limbal region;
- Absence of any one of the following structures in the limbal region underneath the pterygium: (1) epithelial basal cells with dark cytoplasm and reflective cell borders; (2) at least two prominent palisade ridge structures; (3) at least one circular and/or oval-shaped focal stromal projection;
- Informed consent signed by patient or legal guardian; Having the ability to comply with study assessments for the full duration of the study.
- Limbal stem cell deficiency by ocular surface disorders other than pterygium;
- Inability to determine whether the palisades of Vogt underneath the pterygium is absent or not using in vivo confocal microscopy;
- High myopia with a spherical equivalent of -15.0 D or less;
- Corneal or ocular surface infection within 30 days prior to study entry;
- Ocular surface malignancy;
- Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
- Renal failure with creatinine clearance< 25ml/min;
- Alanine aminotransferase > 40IU/L, or aspartate aminotransferase > 40IU/L;
- Platelet levels < 150,000 or > 450,000 per microliter;
- Hemoglobin < 12.0 g/dL (male) or < 11.0 g/dL (female);
- Prothrombin time > 16s and activated partial thrombin time > 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;
- Pregnancy (positive test) or lactation;
- Participation in another simultaneous medical investigation or clinical trial;
- Severe cicatricial eye disease;
- Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;
- Severe dry eye disease as determined by Schirmer's test < 2mm at least in one eye;
- Any medical or social condition that in the judgement of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;
- Signs of current infection, including fever and treatment with antibiotics;
- Active immunological diseases;
- History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Restoration of corneal surface 1 year Restoration of a completely epithelized, stable, and avascular corneal surface
- Secondary Outcome Measures
Name Time Method Reconstruction of palisades of Vogt 1 year To observe the reconstruction of palisades of Vogt using in vivo confocal microscopy.
Corneal haze measurement 1 year To observe the scatter of corneal haze using in vivo confocal microscopy
Recurrence of pterygium 1 year To observe recurrence of pterygium using slit-lamp microscopy
Best corrected visual acuity 1 year To assess changes of best corrected visual acuity using ETDRS chart
Corneal power and astigmatism 1 year To assess changes of corneal power and astigmatism using autorefractor keratometer
Trial Locations
- Locations (1)
Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity
🇨🇳Guangzhou, Guangdong, China
Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity🇨🇳Guangzhou, Guangdong, ChinaYingfeng Zheng, M.D. Ph.D.Contact